Jay Kim

CEO

Country

City

South Korea

Industry

Pharmaceuticals

Skill

Lead Change, Drug Design, Cheminformatics, GPCRs, Target Identification, QSAR, Business Development, Strategic Planning, CMC development, Clinical Development, CMC Regulatory Affairs, Biomarkers, Protein Engineering, Docking, Computational Chemistry, Pharmaceutical Research, High Throughput Screening, Drug Metabolism, Homology Modeling, Science

Experience

CEO

Therasid Bioscience

2017-6 - Present · 9 yrs 4 mos

Seongnam, Gyeonggi-do, Korea

We are focusing on NASH and Neurodegenerative disease. In April, website of Therasid Bioscience was open at http://therasidbio.com.

Senior Director

EnzyChem Lifesciences US Corporation

2015-5 - 2017-3 · 1 yr 11 mos

Research and Development (R&D) Alliance for disease fields of cancer, immune related disease and Alzheimer's disease. Business development for New Drug pipeline EC-18 which can be treated to cancer patients in Chemotherapy-Induced Neutropenia. Assistant of Dr.Chong, SVP, EnzyChem Lisciences US Corporation, in terms of license-out.

Director

EnzyChem Lifescience

2015-1 - 2017-3 · 2 yrs 3 mos

15F, Trust Tower, 60, Mabang-ro, Seocho-gu, Seoul, Korea

Responsible for global clinical trial of EC-18 as an oral treatment for Neutropenia in cancer patients R&D Alliance for preclinical and discovery research Regulatory Affair for EC-18 in MFDS & FDA Principal Investigator of KDDF programs for EC-18 as a treatment of neutropenia CMC document packaging for US IND of EC-18 Division of New Drug Development

Director

EnzyChem Lifesciences

2015-2 - 2015-9 · 8 mos

Responsible for scientific fields of Health Functional Food sales as a immune modulator in Korea and Worldwide. Responsible for Regulatory Affair of immune modulator, PLAG in Korean FDA.